Biocartis Group NV

Major Shareholding Notification • Nov 24, 2020

Transparency notification Form TR-1 BE PART I

19

+

+

수

+

1 2

【

十

1) Status of the notification

Final

2) Issuer

Name BIOCARTIS ldentification number 0505-640-808

3) Reason for the notification

Acquisition or disposal of voting securities or voting rights Downward crossing of the lowest threshold

4) Notification by

A parent undertaking or a controlling person

5) Persons subject to the notification requirement_

Name	Address (for legal entities)
Debiopharm Innovation Fund S.A.	Chemin Messidor 5-7, 1006 Lausanne, Switzerland (formerly Rue de Levant 146, 1920 Martigny, Switzerland)
Apres-Demain S.A. (formerly Après-Demain Holding S.A.)	Chemin Messidor 5-7, 1006 Lausanne, Switzerland
Thierry Mauvernay	Chemin du Praz-Buchilly 113, 1000 Lausanne 25, Switzerland

6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)

	Name	Address (for legal entities)
	Please continue entering the information in part II concerning the persons referred to in Sections 5 and 6	Part II
7) Date on which the threshold is crossed
		19.11.2020 (DD/MM/YYYY)
8) Threshold that is crossed (in %)
		If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10
9) Denominator

Please enter the denominator before filling in the data

10) Notified details

A) Voting rights	Previous notification	After the transaction
	# of voting rights		# of voting rights		% of voting rights
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Thierry Mauvernay	0	0		0.00%
Après-Demain S.A. (formerly Après- Demain Holding S.A.)	0	0		0.00%
Debiopharm Innovation Fund S.A.	2 750 304	1 662 963		2.95%
Subtotal	2 750 304	662 963		2.95%
TOTAL		1 662 963	0	2.95%	0.00%

56 382 088

Start with "groups" of holders. Add subtotals with Z, and then finish with the persons who are "alone".
For groups, start with the ultimate controlling natural person or l

B) Equivalent financial instruments After the transaction
	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised		Settlement
						ー
	Type of financial instrument			0	% of voting rights 0.00%

The totals will be updated once you have clicked on

TOTAL (A & B)				# of voting rights % of voting rights
		CALCULATE	1 662 963	2.95%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Debiopharm Innovation Fund S.A. is controlled by Après-Demain Holding S.A.), which is controlled by Mr. Thierry
Mauvernay

12) In case of proxy voting for only one GM

again	voting rights as of
		will hold will cease to hold / will hold will hold will hold will hold will will

13) Additional information

Done at Lausanne, Switzerland

19.11.2020 (DD/MM/YYYY) On

Name & capacity | Thierry Mauvernay, President and Delegate of the Board

Après-Demain S.A., President and Delegate of the Board

Debiopharm Innovation Fund S.A., President and Delegate of the Board

Signature
Signature
Signature